Eribulin mesylate exerts antitumor effects via CD103

Eribulin mesylate (ERB) is a synthetic analog of halichondrin B, inhibiting tumor cell growth by disrupting microtubule function. Recently, anticancer drugs have been shown to not only act directly on tumor cells but also to exert antitumor effects by modifying the tumor environment. Although ERB ha...

Full description

Bibliographic Details
Published in:	OncoImmunology
Main Authors:	Kazumasa Oya, Yoshiyuki Nakamura, Rei Watanabe, Ryota Tanaka, Yuki Ichimura, Noriko Kubota, Yutaka Matsumura, Hideaki Tahara, Naoko Okiyama, Manabu Fujimoto, Toshifumi Nomura, Yasuhiro Fujisawa
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-12-01
Subjects:	antitumor effect CD103 eribulin mesylate immune checkpoint resident memory T cells
Online Access:	https://www.tandfonline.com/doi/10.1080/2162402X.2023.2218782

Similar Items

Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes
by: Lan Chen, et al.
Published: (2024-05-01)

Eribulin mesylate induces bone mass loss by promoting osteoclastic bone resorption in mice
by: Takahiro Ishizaka, et al.
Published: (2023-06-01)

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas
by: Jonathan Noujaim, et al.
Published: (2016-01-01)

Efficacy of Eribulin in Soft Tissue Sarcomas
by: Edward Phillips, et al.
Published: (2022-03-01)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
by: Koliou P, et al.
Published: (2018-02-01)

Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation
by: Hyemi Ko, et al.
Published: (2022-04-01)

Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial
by: Tetsu Hayashida, et al.
Published: (2018-06-01)

Cutaneous Angiosarcoma: The Possibility of New Treatment Options Especially for Patients with Large Primary Tumor
by: Yasuhiro Fujisawa, et al.
Published: (2018-03-01)

Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting
by: Sarah S. Mougalian, et al.
Published: (2018-09-01)

Eribulin alongwith capecitabine in relapsed carcinoma breast- a retrospective single-Institutional study.
by: Soumita Poddar, et al.
Published: (2023-08-01)

Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma
by: Miaomiao Zhang, et al.
Published: (2025-01-01)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
by: Sonam Mittal, et al.
Published: (2023-09-01)

Stathmin expression alters the antiproliferative effect of eribulin in leiomyosarcoma cells
by: Mana Azumi, et al.
Published: (2022-12-01)

CLINICAL ECONOMIC ANALYSIS OF USING ERIBULIN (HALAVEN®) FOR TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
by: S. L. Plavinsky, et al.
Published: (2016-02-01)

Microenvironment-related predictive markers of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic breast cancer: pilot study
by: L. A. Tashireva, et al.
Published: (2022-01-01)

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
by: Sakura Iizumi, et al.
Published: (2017-12-01)

Eribulin in Heavily Pre-Treated Metastatic Breast Cancer: A Case Series
by: Andini Kartikasari, et al.
Published: (2025-04-01)

Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study
by: E. I. Kovalenko, et al.
Published: (2021-12-01)

Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer
by: Jean-David Fumet, et al.
Published: (2018-08-01)

Eribulin in Metastatic Breast Cancer: Actual Clinical Practice
by: A. V. Sultanbaev, et al.
Published: (2023-04-01)

Eribulin Effectiveness and Safety in Metastatic Triple-Negative Breast Cancer: A Narrative Review
by: Herleeyana Meriyani, et al.
Published: (2025-02-01)

Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea
by: Tremblay G, et al.
Published: (2016-09-01)

Commentary on “time-dependent selected reaction monitoring-based GC-MS/MS method for estimation of genotoxic impurities in a new antibacterial agent: alalevonadifloxin mesylate”
by: D. J. Snodin, et al.
Published: (2020-11-01)

Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity
by: İshak Suat Övey, et al.
Published: (2020-03-01)

Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
by: Mengqian Ni, et al.
Published: (2024-09-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-09-01)

Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia
by: Malkan Umit Y., et al.
Published: (2018-12-01)

Therapeutic efficacy of a four-year treatment with eribulin in a patient with uterine leiomyosarcoma: A case report
by: Motoki Matsuura, et al.
Published: (2023-06-01)

10 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practice
by: I. V. Kolyadina
Published: (2021-10-01)

Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin
by: Meng-Xia Su, et al.
Published: (2024-02-01)

Melasma-like hyperpigmentation: A rare side effect of imatinib mesylate
by: Shreya Agrawal, et al.
Published: (2023-01-01)

PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin
by: Bahram Sharif-Askari, et al.
Published: (2023-03-01)

Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer
by: Mengya Feng, et al.
Published: (2024-12-01)

Prognostic significance of neutrophil to lymphocyte ratio in patients with metastatic breast cancer on the background of eribulin therapy
by: A. V. Zyuzyukina, et al.
Published: (2022-09-01)

Nafamostat mesylate augments survival in rats afflicted by exertional heat stroke
by: Qingwei Lin, et al.
Published: (2025-05-01)

Determination of imatinib mesylate and erlotinib hydrochloride in mice plasma using ultrahigh performance liquid chromatography method
by: Gülen Melike Demir, et al.
Published: (2018-08-01)

Effects of Eribulin on the RNA Content of Extracellular Vesicles Released by Metastatic Breast Cancer Cells
by: Matteo Giulietti, et al.
Published: (2024-03-01)

Generalized lichenoid drug eruption associated with imatinib mesylate therapy
by: Sudip Kumar Ghosh
Published: (2013-01-01)

Application of nafamostat mesylate for anticoagulation in hemoperfusion therapy in patients with bromadiolone poisoning: Case reports
by: Weiwei Qian, et al.
Published: (2023-09-01)